Brentuximab Vedotin + Chemotherapy for PTCL: Study Results
Brentuximab Vedotin Plus CHP Regimen Shows Promise as First-Line Treatment for PTCL
Table of Contents
A recent real-world study has highlighted the effectiveness and safety of combining brentuximab vedotin (BV) with a cyclophosphamide, doxorubicin, and prednisone (CHP)-like regimen as a first-line treatment for patients diagnosed with peripheral T-cell lymphoma (PTCL).The findings suggest this combination could be a valuable option for newly diagnosed PTCL patients.
Understanding Peripheral T-Cell Lymphoma (PTCL)
Peripheral T-cell lymphoma (PTCL) is a diverse group of aggressive non-Hodgkin lymphomas that arise from mature T-cells. These lymphomas are generally less common and frequently enough more challenging to treat than their B-cell counterparts. PTCL encompasses a range of subtypes, each with its own characteristics and treatment considerations.
New Study Insights: BV + CHP-like Regimen in PTCL
Investigators in a new study retrospectively analyzed clinical data from patients with PTCL who received BV in combination with a CHP-like regimen. The median age of the patients included in the analysis was 57 years, with a range from 22 to 86 years.
The study revealed several key outcomes:
Treatment Cycles: Patients received a median of 6 cycles of BV, with the number of cycles administered ranging from 2 to 8.
Response Rates: After a median follow-up of 35.2 months,the overall response rate (ORR) was an notable 80%. Notably, 44% of patients achieved a complete response (CR).
Subtype Specifics: For patients with the ALK-positive anaplastic large cell lymphoma subtype, the CR rate was even higher, reaching 70.6%.
Survival Data: The median progression-free survival (PFS) was 39.7 months. While the median overall survival (OS) was not reached, the 1-year OS rate stood at 90%, indicating strong initial survival outcomes.
Factors Influencing Outcomes and Adverse Events
The study identified bone marrow infiltration at diagnosis as the sole factor associated with poorer overall survival.
Regarding safety, the most frequently observed adverse event was neutropenia, occurring in 81.3% of patients. Peripheral neuropathy was reported in 16.7% of patients. These side effects are generally manageable and align with known profiles of the drugs used.
Expert Conclusion
“This real-world study suggests that BV combined with a CHP-like regimen is an effective and safe first-line treatment for patients with newly diagnosed PTCL,” the authors concluded in their publication.This real-world evidence supports the potential of this combination therapy in clinical practice.
References
- Guan F, Zhang Y, Guo X, et al. brentuximab vedotin plus CHP-like regimen for the first-line treatment of PTCL patients: a real-world single center study. Ann Hematol. Published online July 22, 2025. doi:10.1007/s00277-025-06507-7
- Dharmani C, Unni S, Pham N, et al. Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma. Future Oncol. 2024;20(15):1013-1030. doi:10.2217/FON-2023-0615